NCT06934044View on ClinicalTrials.gov

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

May 8, 2028

Study Completion Date

May 8, 2028

Conditions
Multiple Myeloma
Interventions
DRUG

Cevostamab

Cevostamab will be administered intravenously on a 21-day cycle.

DRUG

Tocilizumab

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Trial Locations (5)

301636

RECRUITING

Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin

325035

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

430030

RECRUITING

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

510060

RECRUITING

Sun yat-sen University Cancer Center, Guangzhou

Unknown

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY